Follow RT on In a major breakthrough for Russia’s Sputnik V Covid-19 vaccine, the prestigious British medical journal The Lancet has published preliminary Phase III trial results showing it is highly effective – notably, for all age groups.
Data from 19,866 volunteers – 4,902 of whom were in the placebo group – showed that Sputnik V had an overall efficacy of 91.6 percent, rising to 91.8 percent among the group of 2,144 volunteers over the age of 60, according to the interim results of the Phase III clinical trial published in the Lancet on Tuesday.
At the end of the study, there were 62 confirmed Covid-19 cases in the placebo group and only 16 in the vaccine group. Sputnik V proved to be 100 percent effective in preventing the development of severe cases.
A vaccine for all mankind: Sputnik V s efficacy in fighting COVID-19 is validated by internationally peer reviewed data published in The Lancet
In an interim analysis of a Phase III clinical trial, Sputnik V
showed
Efficacy of Sputnik V against COVID-19 was reported at 91.6%.
- Analysis included data on 19,866 volunteers, who received both the first and second doses of the Sputnik V vaccine or placebo at the final control point of 78 confirmed COVID-19 cases.
- Efficacy in the elderly group of 2,144 volunteers over 60 years old was 91.8% and did not differ statistically from the 18-60 group.
Sputnik V provides full protection against severe cases of COVID-19.
The News Scroll 02 February 2021
Last Updated at 7:31 pm | Source: PTI
Russian COVID vax found 91.6pc efficient in Phase III trial: RDIF Outlook February 02, 2021 19:31 IST Russian COVID vax found 91.6pc efficient in Phase III trial: RDIF outlookindia.com 1970-01-01T05:30:00+0530
New Delhi, Feb 2 (PTI) The Gamaleya National Research Centre and the Russian Direct Investment Fund (RDIF) on Tuesday said that interim results of a Phase III clinical trial of COVID-19 vaccine Sputnik V showed 91.6 per cent efficacy against the pandemic. Medical journal The Lancet has published interim results of a Phase III clinical trial of Sputnik V, confirming the vaccine s high efficacy and safety, they said in a joint statement.
To improve the performance of our website, show the most relevant news products and targeted advertising, we collect technical impersonal information about you, including through the tools of our partners. You can find a detailed description of how we use your data in our Privacy Policy. For a detailed description of the technologies, please see the Cookie and Automatic Logging Policy.
By clicking on the Accept & Close button, you provide your explicit consent to the processing of your data to achieve the above goal.
You can withdraw your consent using the method specified in the Privacy Policy.
Accept & Close
Sputnik International